Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate

Detalles Bibliográficos
Autores principales: Wang, Jiang-Yi, Yu, Guo-Peng, Li, Long, Lin, Guo-Wen, Ye, Ding-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785553/
https://www.ncbi.nlm.nih.gov/pubmed/35074001
http://dx.doi.org/10.1186/s40779-021-00364-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785553/
https://www.ncbi.nlm.nih.gov/pubmed/35074001
http://dx.doi.org/10.1186/s40779-021-00364-x

Ejemplares similares